Sun Pharma adds $1.6m sterile manufacturing line in Guwahati, India

By Flora Southey

- Last updated on GMT

(Image: Getty/dk_photos)
(Image: Getty/dk_photos)

Related tags Sun pharma India

Sun Pharma has installed a parenteral drug production line in Guwahati for the manufacture of sterile products.

According to the firm, the Rs 120 crores ($1.6m) investment will enhance Sun Pharma’s capacity to manufacture lyophilized vials, liquid ampoules, and eye drops at the 14-acre Guwahati site.

Located in India’s eastern state of Assam, the Guwahati facility also houses granulation, tablet compression, and capsule filling capabilities.

Sun Pharma’s managing director, Dilip Shanghvi, said this latest investment responds to a governmental push for increased industrial activities and employment opportunities in Assam.

“Sun Pharma is committed to the government’s ‘Make in India’ initiative,” ​Shanghvi told delegates at the production line launch.

“In the next few years, the Guwahati plant is expected to become of the largest facilities in our network to manufacture sterile products,” ​he added.

Despite manufacturing setbacks in Gujarat​ and Halol​ earlier in the year, Sun Pharma recently announced regulatory success in the US for two separate drug products.

In August, the firm launched​ its extended-release Kapspargo Sprinkle drug product for the treatment of hypertension, angina pectoris or heart failure.

The following month, Sun Pharma announced​ its eye disease treatment, Cequa (cyclosporine ophthalmic solution) had received US Food and Drug Administration approval. 

Related news

Show more

Related products

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Follow us